Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOENIX-BTC first-line advanced biliary tract cancer study
jRCT2071260018Phase 3Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of futibatinib and zimberelimab in biliary cancer (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Jun 2026; status: recruiting.
02
Drugs
futibatinibzimberelimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT2071260018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260018.